Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

— AFACET  

Official title:

Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03727724
• Other study ID #: M18ACX
• Status: Completed
• Phase: Phase 2
• Start date: December 4, 2018
• Est. completion date: September 6, 2022

Study information

• Verified date: October 2023
• Source: The Netherlands Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: September 6, 2022
• Est. primary completion date: September 6, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathologically or cytologically confirmed stage IV non-small cell lung cancer, harboring an EGFR exon 20 insertion mutation.
• 18 years or older at time of study entry.
• Life expectancy of at least three months.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 1).
• Measurable disease, according to RECIST 1.1.
• At baseline adequate fresh or archived tissue from a histological biopsy or a cellblock obtained by fine needle aspiration of a tumor lesion that is not radiated prior to biopsy, must be available. Baseline tissue samples must have been obtained after the last line of systemic therapy prior to study entry.
• Adequate normal organ and marrow function as defined below:
• Absolute leukocyte count = 3 x 109/L (> 3000 per mm3)
• Platelet count = 75 x 109/L (>75,000 per mm3)
• Aspartate amino transferase (AST) or alanine amino transferase (ALT) = 3 x institutional upper limit of normal unless liver metastases are present, in which case it must be = 5x upper limit of normal (ULN).
• Serum creatinine clearance >30 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance.
• Women of child-bearing potential: these subjects must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment and agree to use highly effective contraception, as defined in section 5.2.2, from 7 days prior to enrollment, throughout the treatment period and for seven months after completion of the treatment with cetuximab.
• Males must agree to take appropriate precautions to avoid fathering a child from the first dose of study treatment through 3 months after the final administration of investigational drugs.
• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
• Ability to give written informed consent before patient registration.

Exclusion Criteria:

• Participation in another clinical study with an investigational product during the last 2 weeks.
• Prior treatment with EGFR targeting antibodies (prior treatment with EGFR TKI's is allowed).
• Other active malignancy.
• History of hypersensitivity to afatinib or cetuximab.
• Major surgery (excluding diagnostic procedures e.g. mediastinoscopy or video assisted thoracic surgery (VATS) biopsy) within 28 days of the start of study treatment.
• Radiotherapy less than two weeks prior to the start of study treatment.
• Symptomatic brain metastases.
• Breast feeding is not allowed during study treatment.
• Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, myocardial infarction within 12 months prior to the study entry, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety and anti-tumor activity of the test drugs.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• Afatinib
Tablet
• Cetuximab
Injection

Locations

Country	Name	City	State
Netherlands	Antoni van Leeuwenhoek	Amsterdam	North-Holland
Netherlands	VU Medical Center	Amsterdam
Netherlands	University Medical Center Groningen	Groningen
Netherlands	Maastricht UMC+	Maastricht

Sponsors (3)

Lead Sponsor	Collaborator
The Netherlands Cancer Institute	Boehringer Ingelheim, Merck Serono International SA

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Genetic profiling to assess predictors of response and resistance - circulating free (cf)DNA	cfDNA samples will be collected to assess predictors of response and resistance.	At baseline, cycle 1 day 15 and at treatment discontinuation (expected 6 months after start)
Primary	Disease control rate after 18 weeks	To determine the disease control rate at 18 weeks of afatinib and cetuximab treatment in patients with NSCLC harboring an EGFR exon 20 insertion mutation.	18 weeks
Secondary	Objective tumor response	Objective tumor response (complete response and partial response)determined by RECIST v1.1.	Scans every 6 weeks until tumor progression, start of another treatment or death.
Secondary	Safety (intensity and incidence of adverse events)	Safety as indicated by intensity and incidence of adverse events, graded according to NCI CTCAE Version 4.03.	Up to 30 days after last study drug intake.
Secondary	Duration of response (DOR)	Time from documentation of tumor response to disease progression	Scans every 6 weeks until tumor progression
Secondary	Progression free survival	Time from the date of start treatment to the date of the first documented tumor progression as determined by RECIST1.1, or death due to any cause	Until progression, every 6 weeks up to progression
Secondary	Overall survival	Time form date of start treatment to the date of death from any cause	Every 6 weeks up to death